Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 2	2026-06-04		NCT06282978

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
PETHEMA Foundation	21

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
C.H. de Toledo (Virgen de la Salud)	Toledo	Spain	1
CHU de Gran Canaria Doctor Negrín	Las Palmas de Gran Canaria	Spain	1
Complejo Asistencial Universitario de León	León	Spain	7
H. Clínic i Provincial de Barcelona	Barcelona	Spain	1
Hospital Clínico Universitario de Santiago ~ CHUS	Santiago de Compostela	Spain	1
Hospital Clínico Universitario Salamanca	Salamanca	Spain	1
Hospital Clínico Universitario Virgen de la Arrixaca	El Palmar	Spain	14
Hospital de Cabueñes	Gijón	Spain	5
Hospital Son Llàtzer	Palma de Mallorca	Spain	3
Hospital Universitario de Jerez de la Frontera	Jerez de la Frontera	Spain	4
Hospital Universitario Lucus Augusti	Lugo	Spain	12
Hospital Universitario Marqués de Valdecilla	Santander	Spain	40
Institut Catala d'Oncologia (ICO) Badalona - Hospital Universitari Germans Trias i Pujol	Badalona	Spain	1